Previous 10 | Next 10 |
First data to demonstrate the contribution of CD6-ALCAM and T-cells to the pathogenesis of lupus nephritis Largest, most comprehensive cohort of lupus nephritis patients analy z ed to date supports soluble ALCAM as a biomarker for disease activity Equillium, Inc....
Data from EQUATE study continues to show rapid and durable complete responses, resulting in clinically meaningful reduction in corticosteroid use 79% of responders maintained or achieved a complete response at six months Pivotal study in aGVHD to commence in early ...
Equillium (NASDAQ:EQ): Q3 GAAP EPS of -$0.35 misses by $0.01. Revenue of $0M Press Release Cash, cash equivalents and short-term investments totaled $90.7 million as of September 30, 2021. For further details see: Equillium EPS misses by $0.01
Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Reported decrease in proteinuria observed in subgroup of patients with lupus following two doses of itolizumab Reported interim safety data from first c...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in fireside chat presentations at the Stifel 2021 Virtual Healthcare Co...
Sustained decrease in proteinuria observed in subgroup of patients with systemic lupus erythematosus, without lupus nephritis, following two doses of itolizumab Dose dependent decreases in inflammatory marker CD6 following itolizumab administration Equillium, Inc. (N...
Itolizumab was well tolerated in patients with moderate to severe uncontrolled asthma Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today reported...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the 63 rd annual meeting of the America...
Subgroup analyses of lupus patients (without lupus nephritis) that had elevated baseline proteinuria and albuminuria shows reduction of 42% and 54%, respectively, by Day 57 Itolizumab was well tolerated at doses ranging from 0.4 to 2.4 mg/kg Equillium, Inc. (Nasdaq: ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Q2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutic...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...